LMR Partners’s Clearside Biomedical CLSD Stock Holding History

LMR Partners’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1,536	Closed	-$15K	–	420
2019 Q3	$15K	Hold	1,536	–	–	﹤0.01%	407
2019 Q2	$22K	Buy	+1,536	New	+$27.4K	﹤0.01%	399

Other funds holding CLSD

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

LMR Partners's CLSD Position: Q4 2019 in Review

LMR Partners sold out of Clearside Biomedical (CLSD) in Q4 2019, closing a stake of 1,536 shares — an estimated $15K sold.

LMR Partners first reported a position in CLSD in Q2 2019 and held it in 2 quarters. The position peaked at $22K in Q2 2019. 47 funds tracked by Wall St. Rank hold CLSD as of Q4 2019.

LMR Partners reported no remaining Clearside Biomedical position as of Q4 2019 after selling out during the quarter.
LMR Partners sold 1,536 Clearside Biomedical shares in Q4 2019, an estimated $15K.
LMR Partners first reported a position in Clearside Biomedical in Q2 2019 and held it in 2 quarters.
LMR Partners's Clearside Biomedical position peaked at $22K in Q2 2019.
47 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2019.

Based on LMR Partners's 13F filing for Q4 2019, filed 14 Feb 2020.